CARNMT1: A Potential Drug Target and Biomarker for Diseases (G138199)

Target Name: CARNMT1

NCBI ID: G138199

CARNMT1

CARNMT1: A Potential Drug Target and Biomarker for Diseases

CARNMT1, also known as CARME_HUMAN, is a protein that is expressed in human tissues and is involved in the regulation of cell growth, differentiation, and metabolism. It is a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The carmelatin family proteins are a class of proteins expressed in human tissues and are involved in regulating cell growth, differentiation and metabolism. It is a potential drug target (or biomarker) and plays an important role in cancer, neurodegenerative diseases and autoimmune diseases.

CARNMT1 is a transcription factor mainly expressed in neural tissue, embryonic and liver tissue. Interacting with other proteins, CARNMT1 can regulate a variety of cellular processes, including cell cycle, cell proliferation, apoptosis, and cell metabolism. In neurons, CARNMT1 interacts with proteins necessary for neuronal survival and can affect neuronal survival and apoptosis. In the liver, CARNMT1 interacts with cell growth regulatory factors and can affect the proliferation and metabolism of liver cells.

CARNMT1 is also associated with many diseases, including neurological diseases, immune system diseases and cancer. For example, in Parkinson's disease, increased expression levels of the CARNMT1 gene are associated with the onset and progression of the disease. In liver cancer, CARNMT1 gene expression levels are also increased, which is related to the progression and treatment response of liver cancer.

Because CARNMT1 is expressed in a variety of diseases, it is considered a potential drug target. Studies have also shown that inhibition of CARNMT1 can significantly inhibit tumor growth and cell proliferation. In addition, studies have shown that CARNMT1 inhibitors can improve patients' quality of life and prolong survival.

In addition to being a drug target, CARNMT1 may also serve as a biomarker. Because CARNMT1 is expressed in a variety of diseases, it can be used to detect early stages of disease and monitor the effectiveness of treatments. For example, in lung cancer, reduced CARNMT1 expression levels can serve as a biomarker for tumor recurrence.

In addition, CARNMT1 also interacts with

Protein Name: Carnosine N-methyltransferase 1

Functions: N-methyltransferase that catalyzes the formation of anserine (beta-alanyl-N(Pi)-methyl-L-histidine) from carnosine. Anserine, a methylated derivative of carnosine (beta-alanyl-L-histidine), is an abundant constituent of vertebrate skeletal muscles. Also methylates other L-histidine-containing di- and tripeptides such as Gly-Gly-His, Gly-His and homocarnosine (GABA-His)

The "CARNMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CARNMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets